Valneva SE
VALN
Positions held
Your positionsVALN isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $539.55M | Enterprise value | $628.25M | Trailing P/E | — | Forward P/E | 4.78 |
| PEG | — | Price / book | 5.72 | Beta | 1.26 | Dividend yield | 0.00% |
| Revenue growth | -27.7% | Earnings growth | — | Gross margin | -41.7% | Operating margin | -74.9% |
| Profit margin | -110.3% | ROE | -117.8% | ROA | -16.7% | Debt / equity | 2.59 |
| Current ratio | 2.16 | Free cash flow | -$42.50M | Analyst recommendation | buy | Mean target | $12.25 |
| 52w high | $12.18 | 52w low | $4.75 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $34.9M | $30.9M | $47.7M | $29.4M | $48.3M | — |
| Op margin | -74.9% | -76.7% | -58.1% | -127.0% | -22.0% | — |
| Net income | -$31.2M | -$32.1M | -$50.0M | -$44.4M | -$11.6M | — |
| Gross margin | 4.6% | 15.3% | 24.4% | 18.7% | 50.1% | — |
| Gross profit | $1.6M | $4.7M | $11.6M | $5.5M | $24.2M | — |
| Operating income | -$26.2M | -$23.7M | -$27.7M | -$37.3M | -$10.6M | — |
- Revenue +13% vs prior quarter ($35M vs $31M).
- Gross margin 4.6% (was 15.3% prior quarter).
- Operating margin expanded to -74.9%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $175M | $170M | $154M | $361M | — |
| Op margin | -46.7% | -45.9% | -53.4% | -31.4% | — |
| Net income | -$115M | -$12.2M | -$101M | -$143M | — |
| Gross margin | 38.7% | 41.9% | 34.4% | 10.2% | — |
| Gross profit | $67.5M | $71.0M | $52.8M | $36.9M | — |
| Operating income | -$81.6M | -$77.8M | -$82.1M | -$113M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Valneva Shares Fall as UK Withdraws Approval for Ixchiq Chikungunya Vaccine
2026-10-08 · Valneva Says UK Revokes Chikungunya Virus Vaccine's Marketing Authorization; Shares Down Pre-Bell
2026-10-07 · VALN Stock Plunges 7% After-Hours As UK Revokes Valneva’s IXCHIQ Authorization In Latest Market Setback
2026-10-07 · Valneva ADRs fall as UK revokes IXCHIQ marketing authorization
2026-10-07 · Valneva Provides Update on IXCHIQ® in the United Kingdom
2026-10-05 · Declaration of shares and voting rights - Status as of September 30, 2026
2026-09-24 · Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost?
2026-09-15 · Pfizer (PFE), Valneva (VALN) Lyme Vaccine Moves to EMA Review Despite Phase 3 Caveat
2026-09-04 · Declaration of shares and voting rights - Status as of August 31, 2026
2026-08-28 · The Bull Case For Pfizer (PFE) Could Change Following New COVID And Lyme Vaccine Milestones - Learn Why
2026-08-20 · Valneva (VALN) Q2 2026 Earnings Call Transcript
Price (daily)
Full chart · RSI · MACD · patterns